Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846586 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,134
- Enrollment target
NCT00846586 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,134 participants.
The verdict
NCT00846586, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,134 participants
- Enrollment target
Study Summary
This study assessed the efficacy and safety of indacaterol (150 µg once daily \[od\]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD)
Interventions
- DRUG Placebo to indacaterol
- DRUG Indacaterol 150 μg
- DRUG Tiotropium 18 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,134 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846586
The ClinicalTrials.gov registry entry for NCT00846586 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo to indacaterol is the first listed.
NCT00846586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00846586 about?
NCT00846586 is a clinical study titled "Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease". This study assessed the efficacy and safety of indacaterol (150 µg once daily \[od\]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD)
What is the current status of trial NCT00846586?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,134 participants. The study started on 2009-03. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00846586?
The interventions under investigation include: Placebo to indacaterol (DRUG), Indacaterol 150 μg (DRUG), Tiotropium 18 μg (DRUG).
Who is sponsoring clinical trial NCT00846586?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.